Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386138287> ?p ?o ?g. }
- W4386138287 endingPage "85" @default.
- W4386138287 startingPage "71" @default.
- W4386138287 abstract "The Centers for Disease Control and Prevention estimate that Clostridioides difficile (C. difficile) causes half a million infections (CDI) annually and is a major cause of total infectious disease death in the United States, causing inflammation of the colon and potentially deadly diarrhea. We recently reported the isolation of ADS024, a Bacillus velezensis (B. velezensis) strain, which demonstrated direct in vitro bactericidal activity against C. difficile, with minimal collateral impact on other members of the gut microbiota. In this study, we hypothesized that in vitro activities of ADS024 will translate in vivo to protect against CDI challenge in mouse models.To investigate the in vivo efficacy of B. velezensis ADS024 in protecting against CDI challenge in mouse models.To mimic disruption of the gut microbiota, the mice were exposed to vancomycin prior to dosing with ADS024. For the mouse single-dose study, the recovery of ADS024 was assessed via microbiological analysis of intestinal and fecal samples at 4 h, 8 h, and 24 h after a single oral dose of 5 × 108 colony-forming units (CFU)/mouse of freshly grown ADS024. The single-dose study in miniature swine included groups that had been pre-dosed with vancomycin and that had been exposed to a dose range of ADS024, and a group that was not pre-dosed with vancomycin and received a single dose of ADS024. The ADS024 colonies [assessed by quantitative polymerase chain reaction (qPCR) using ADS024-specific primers] were counted on agar plates. For the 28-d miniature swine study, qPCR was used to measure ADS024 levels from fecal samples after oral administration of ADS024 capsules containing 5 × 109 CFU for 28 consecutive days, followed by MiSeq compositional sequencing and bioinformatic analyses to measure the impact of ADS024 on microbiota. Two studies were performed to determine the efficacy of ADS024 in a mouse model of CDI: Study 1 to determine the effects of fresh ADS024 culture and ADS024 spore preparations on the clinical manifestations of CDI in mice, and Study 2 to compare the efficacy of single daily doses vs dosing 3 times per day with fresh ADS024. C. difficile challenge was performed 24 h after the start of ADS024 exposure. To model the human distal colon, an anerobic fecal fermentation system was used. MiSeq compositional sequencing and bioinformatic analyses were performed to measure microbiota diversity changes following ADS024 treatment. To assess the potential of ADS024 to be a source of antibiotic resistance, its susceptibility to 18 different antibiotics was tested.In a mouse model of CDI challenge, single daily doses of ADS024 were as efficacious as multiple daily doses in protecting against subsequent challenge by C. difficile pathogen-induced disease. ADS024 showed no evidence of colonization based on the observation that the ADS024 colonies were not recovered 24 h after single doses in mice or 72 h after single doses in miniature swine. In a 28-d repeat-dose study in miniature swine, ADS024 was not detected in fecal samples using plating and qPCR methods. Phylogenetic analysis performed in the human distal colon model showed that ADS024 had a selective impact on the healthy human colonic microbiota, similarly to the in vivo studies performed in miniature swine. Safety assessments indicated that ADS024 was susceptible to all the antibiotics tested, while in silico testing revealed a low potential for off-target activity or virulence and antibiotic-resistance mechanisms.Our findings, demonstrating in vivo efficacy of ADS024 in protecting against CDI challenge in mouse models, support the use of ADS024 in preventing recurrent CDI following standard antibiotic treatment." @default.
- W4386138287 created "2023-08-25" @default.
- W4386138287 creator A5002151898 @default.
- W4386138287 creator A5004281357 @default.
- W4386138287 creator A5044970489 @default.
- W4386138287 creator A5047441756 @default.
- W4386138287 creator A5048633162 @default.
- W4386138287 creator A5051309498 @default.
- W4386138287 creator A5058164754 @default.
- W4386138287 creator A5070606271 @default.
- W4386138287 creator A5075957811 @default.
- W4386138287 date "2023-08-24" @default.
- W4386138287 modified "2023-10-11" @default.
- W4386138287 title "Novel, non-colonizing, single-strain live biotherapeutic product ADS024 protects against <i>Clostridioides difficile</i> infection challenge <i>in vivo</i>" @default.
- W4386138287 cites W1892179039 @default.
- W4386138287 cites W1905413582 @default.
- W4386138287 cites W1973650764 @default.
- W4386138287 cites W1991067170 @default.
- W4386138287 cites W2010987861 @default.
- W4386138287 cites W2032605132 @default.
- W4386138287 cites W2070879762 @default.
- W4386138287 cites W2071054182 @default.
- W4386138287 cites W2107182849 @default.
- W4386138287 cites W2119634942 @default.
- W4386138287 cites W2123146097 @default.
- W4386138287 cites W2123458607 @default.
- W4386138287 cites W2131038214 @default.
- W4386138287 cites W2145602555 @default.
- W4386138287 cites W2147511770 @default.
- W4386138287 cites W2149711482 @default.
- W4386138287 cites W2152417392 @default.
- W4386138287 cites W2253355615 @default.
- W4386138287 cites W2511217924 @default.
- W4386138287 cites W2574936607 @default.
- W4386138287 cites W2582069104 @default.
- W4386138287 cites W2747390252 @default.
- W4386138287 cites W2774547239 @default.
- W4386138287 cites W2779872789 @default.
- W4386138287 cites W2886257399 @default.
- W4386138287 cites W2893591809 @default.
- W4386138287 cites W2920461446 @default.
- W4386138287 cites W2987329362 @default.
- W4386138287 cites W2991035422 @default.
- W4386138287 cites W3015440105 @default.
- W4386138287 cites W3015470929 @default.
- W4386138287 cites W3029654069 @default.
- W4386138287 cites W3036229416 @default.
- W4386138287 cites W3083900288 @default.
- W4386138287 cites W3175883958 @default.
- W4386138287 cites W3203716493 @default.
- W4386138287 cites W4206302370 @default.
- W4386138287 cites W4206828646 @default.
- W4386138287 cites W4226296560 @default.
- W4386138287 cites W4281655768 @default.
- W4386138287 cites W4281673494 @default.
- W4386138287 cites W4315433046 @default.
- W4386138287 doi "https://doi.org/10.4291/wjgp.v14.i4.71" @default.
- W4386138287 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37727283" @default.
- W4386138287 hasPublicationYear "2023" @default.
- W4386138287 type Work @default.
- W4386138287 citedByCount "0" @default.
- W4386138287 crossrefType "journal-article" @default.
- W4386138287 hasAuthorship W4386138287A5002151898 @default.
- W4386138287 hasAuthorship W4386138287A5004281357 @default.
- W4386138287 hasAuthorship W4386138287A5044970489 @default.
- W4386138287 hasAuthorship W4386138287A5047441756 @default.
- W4386138287 hasAuthorship W4386138287A5048633162 @default.
- W4386138287 hasAuthorship W4386138287A5051309498 @default.
- W4386138287 hasAuthorship W4386138287A5058164754 @default.
- W4386138287 hasAuthorship W4386138287A5070606271 @default.
- W4386138287 hasAuthorship W4386138287A5075957811 @default.
- W4386138287 hasBestOaLocation W43861382871 @default.
- W4386138287 hasConcept C150903083 @default.
- W4386138287 hasConcept C202751555 @default.
- W4386138287 hasConcept C207001950 @default.
- W4386138287 hasConcept C2778980435 @default.
- W4386138287 hasConcept C2779489039 @default.
- W4386138287 hasConcept C501593827 @default.
- W4386138287 hasConcept C523546767 @default.
- W4386138287 hasConcept C54355233 @default.
- W4386138287 hasConcept C55493867 @default.
- W4386138287 hasConcept C61716771 @default.
- W4386138287 hasConcept C71924100 @default.
- W4386138287 hasConcept C86803240 @default.
- W4386138287 hasConcept C89423630 @default.
- W4386138287 hasConceptScore W4386138287C150903083 @default.
- W4386138287 hasConceptScore W4386138287C202751555 @default.
- W4386138287 hasConceptScore W4386138287C207001950 @default.
- W4386138287 hasConceptScore W4386138287C2778980435 @default.
- W4386138287 hasConceptScore W4386138287C2779489039 @default.
- W4386138287 hasConceptScore W4386138287C501593827 @default.
- W4386138287 hasConceptScore W4386138287C523546767 @default.
- W4386138287 hasConceptScore W4386138287C54355233 @default.
- W4386138287 hasConceptScore W4386138287C55493867 @default.
- W4386138287 hasConceptScore W4386138287C61716771 @default.
- W4386138287 hasConceptScore W4386138287C71924100 @default.
- W4386138287 hasConceptScore W4386138287C86803240 @default.
- W4386138287 hasConceptScore W4386138287C89423630 @default.